You searched for supply of essential oils

Supply of essential oil for topical use infringes method of treatment patent claims

by Naomi Pearce | Dec 23, 2020 | Blog, Naomi Pearce

Supply of essential oil for topical use infringes method of treatment patent claims Justice Nicholas’ 96-page judgment in John Hood v Bush Pharmacy Pty Ltd [2020] FCA 1686 raises numerous legal issues including contributory infringement under s. 117 of the Patents Act...

When supply of a staple commercial product is not infringement

by Naomi Pearce, Kate Legge | May 11, 2022 | Blog, Patent Case Summaries

Hood v Down Under Enterprises International Pty Ltd [2022] FCAFC 69 Date: Court: Judges: 4 May 2022 Full Federal Court of Australia Yates, Moshinsky and Rofe JJ Background Mr Hood, the applicant, found a native shrub, Kunzea ambigua, growing on his farm in Tasmania....

Alvotech enters supply agreement with Advanz for five biosimilars including golimumab and vedolizumab in EU, UK and CH following Stada termination

by Bioblast Editor | May 22, 2023 | Biosimilars updates

Alvotech announced that it has entered into a master license and supply agreement with Advanz to commercialise and supply in Europe AVT05 (biosimilar to Janssen’s Simponi® and Simponi Aria® (golimumab)), AVT16 (biosimilar to Takeda’s Entyvio® (vedolizumab)), and three...

Celltrion to supply Vegzelma® (bevacizumab) in Italy and Belgium

by Bioblast Editor | May 11, 2023 | Biosimilars updates

Korea Biomed has reported that Celltrion Healthcare has won bids to supply Vegzelma®, biosimilar to Genentech’s Avastin® (bevacizumab), in Italy and Belgium to treat metastatic colorectal and breast cancer. Celltrion says that it will supply three Italian provinces...

BioBlast® w/e 22 July 2022: Hikma/Celltrion adalimumab deal, Erasca/Lilly cetuximab clinical supply agreement, Celltrion’s tocilizumab clinical trial, Alvotech denosumab study, 100mg/mL Hyrimoz® adalimumab sBLA and Novartis/Sandoz update

by Naomi Pearce | Jul 25, 2022 | BioBlast®, Blog

18 Jul 22 | MENA | Hikma and Celltrion enter into commercialisation agreement for YuflymaTM Hikma Pharmaceuticals announced that it has entered into a commercialisation agreement with Celltrion in relation to Celltrion’s YuflymaTM (biosimilar citrate-free...